CBAY Company Profile and Key Details
CymaBay Therapeutics, Inc.
CBAY Stock Price Chart
Stock Price Today
CymaBay Therapeutics, Inc. (CBAY) stock surged +0.03%, trading at $32.48 on NASDAQ, up from the previous close of $32.47. The stock opened at $32.49, fluctuating between $32.48 and $32.50 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Company Information
| Employees | 101 |
| Beta | 0.32 |
| Sales or Revenue | $31.07M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) stock price is $32.48 in the last trading session. During the trading session, CBAY stock reached the peak price of $32.50 while $32.48 was the lowest point it dropped to. The percentage change in CBAY stock occurred in the recent session was 0.03% while the dollar amount for the price change in CBAY stock was $0.01.
The NASDAQ listed CBAY is part of Biotechnology industry that operates in the broader Healthcare sector. CymaBay Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Ken Boehm
Senior Vice President of HR
Mr. Patrick J. O'Mara
Senior Vice President of Bus. Devel.
Dr. Robert L. Martin
Senior Vice President of Manufacturing & Nonclinical Devel.
Ms. Becki Filice
Senior Vice President of Portfolio & Product Leadership
Mr. Lewis J. Stuart B.A., BA, M.B.A., MBA
Chief Commercial Officer
Dr. Charles A. McWherter Ph.D.
Pres of R&D and Chief Scientific Officer
Dr. Dennis D. Kim M.B.A., M.D., MBA
Executive Officer
Mr. Daniel Menold
Vice President of Fin.
Mr. Sujal A. Shah
Pres, Chief Executive Officer & Director
Mr. Paul T. Quinlan
Gen. Counsel, Chief Compliance Officer & Corporation Sec.
Mr. Harish Shantharam C.F.A.
Chief Financial Officer
CBAY's closing price is 347.32% higher than its 52-week low of $7.26 where as its distance from 52-week high of $32.50 is -0.06%.
Number of CBAY employees currently stands at 101.
Official Website of CBAY is: https://www.cymabay.com
CBAY could be contacted at phone 510 293 8800 and can also be accessed through its website. CBAY operates from 7575 Gateway Boulevard, Newark, CA 94560, United States.
CBAY stock volume for the day was 8.35M shares. The average number of CBAY shares traded daily for last 3 months was 3.94M.
The market value of CBAY currently stands at $3.73B with its latest stock price at $32.48 and 114.79M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com